Egyptian health technology startup Reme-D has secured US$1.45 million in pre-Series A funding to accelerate the production of locally manufactured molecular diagnostic tests and expand its presence across Africa and the Middle East.
The investment will enable the company to increase manufacturing capacity, broaden its regional distribution network, and develop new diagnostic solutions targeting both infectious and non-communicable diseases.
The funding round was led by Anara Impact Capital, with participation from the Global Innovation Fund (GIF), Africa Health Ventures, and a group of additional investors committed to strengthening healthcare innovation in emerging markets.
Founded in 2023 by Salma Tammam, Reme-D specializes in the development and manufacture of molecular diagnostic tests designed for resource-constrained healthcare systems. Its current portfolio includes tests for tuberculosis (TB), HIV, hepatitis, and human papillomavirus (HPV), with an emphasis on affordability and resilience in environments where cold-chain logistics and laboratory infrastructure are limited.
The new capital will support the introduction of additional diagnostic products, including tests for genetic disorders and cancer-related conditions. The company also plans to expand its range of temperature-stable diagnostics, making them easier to transport and store in remote communities and healthcare facilities with limited refrigeration capacity.
Since launching operations, Reme-D has developed and commercialized 30 diagnostic products from its manufacturing facility in Cairo. The company says it has already supplied more than 550,000 diagnostic tests across Egypt, Kenya, and Sudan, demonstrating growing demand for locally produced medical technologies on the continent.
The latest investment follows an earlier funding round in April 2026, when the Global Innovation Fund provided US$500,000 to support the company’s growth.
Speaking about the company’s vision, founder and Chief Executive Officer Salma Tammam said Reme-D aims to remove financial and logistical barriers that prevent millions of people across Africa and the Global South from accessing timely disease diagnosis.
She added that the company is equally committed to demonstrating the global potential of African scientific innovation and women-led technology businesses, while delivering healthcare solutions with measurable social impact.
Commenting on the investment, Mohamed Hussain, Principal at Anara Impact Capital, said Reme-D has demonstrated that world-class molecular diagnostic technologies can be designed and manufactured locally while addressing the practical realities faced by healthcare providers in underserved markets.
He noted that the firm’s scientific capabilities, combined with its focus on accessible healthcare, position Reme-D to expand its impact across the Middle East and Africa (MEA) and potentially into additional international markets.
As African countries continue investing in stronger healthcare systems and local pharmaceutical manufacturing, Reme-D’s expansion reflects a broader trend toward home-grown medical innovation capable of reducing dependence on imported diagnostic technologies while improving access to essential healthcare services.
